ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire is investigating Alnylam Pharmaceuticals for potential federal securities law violations following the company's July 30, 2026 announcement of a $200 million reduction in TTR product sales guidance. The guidance cut, attributed to normalization of growth after initial market launch, triggered a 28.35% intraday stock price decline. The firm is seeking stockholders who suffered losses to participate in potential litigation.

08/04/2026, 7:25 PM • GlobeNewswire

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz is investigating Alnylam Pharmaceuticals for possible federal securities law violations. On July 30, 2026, Alnylam lowered its TTR product sales guidance by approximately $200 million due to slower-than-expected growth in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a 28.35% intraday stock decline, causing investor losses.

08/03/2026, 7:34 PM • GlobeNewswire

ALNYLAM PHARMACEUTICALS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Law firm Kirby McInerney LLP is investigating potential securities fraud claims against Alnylam Pharmaceuticals following the company's announcement on July 30, 2026, that it lowered TTR product sales guidance by approximately $200 million due to normalization of growth in the ATTR-CM market after satisfying pent-up demand. The stock fell 28% ($81.14 per share) to $205.48 on the news.

07/31/2026, 6:54 PM • GlobeNewswire

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200

Atlas Healthcare Fund, managed by VST Capital, showcased its track record of early conviction investments in healthcare, with notable positions in Eli Lilly (entered at $350, now trading above $1,200), Alnylam Pharmaceuticals, TransMedics Group, and Inari Medical. The fund has delivered cumulative net returns of +1,720.9% since inception in January 2020, averaging over 57% annually, by identifying clinically differentiated technologies before mainstream market recognition.

07/17/2026, 8:36 AM • GlobeNewswire

Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines Expand

The global oligonucleotide contract development and manufacturing organization (CDMO) market is experiencing strong growth driven by expanding RNA-targeted medicine pipelines, increased outsourcing of complex synthesis and manufacturing, and rising demand for precision medicine. The market is projected to grow at a 21.81% CAGR through 2031, with contract manufacturing leading at 51.68% market share in 2025. Antisense oligonucleotides dominate at 58.23% revenue, while siRNA is the fastest-growing segment at 23.25% CAGR. Asia-Pacific is the fastest-growing region at 24.56% CAGR, driven by capacity expansion in China, South Korea, and Japan.

07/15/2026, 4:10 AM • GlobeNewswire

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

07/07/2026, 6:42 AM • GlobeNewswire

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.

Alnylam Pharmaceuticals has gained strong analyst support with 21 of 29 analysts rating it as buy or strong buy, with an average price target of $436 (45% upside). The company is transitioning from a clinical biotech to a profitable commercial powerhouse, with Q1 product revenue surging 121% year-over-year to $1.04 billion, driven by its ATTR franchise. The company's pipeline is expanding into mainstream markets like cardiomyopathy and hypertension, supported by a unique RNAi delivery platform that creates a competitive moat. However, the stock trades at a high valuation of 75x trailing earnings, with risks from competitive pricing pressure.

07/02/2026, 6:33 AM • The Motley Fool

Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment

The global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.

05/18/2026, 2:33 PM • GlobeNewswire

Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight

The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.

05/14/2026, 1:00 PM • GlobeNewswire

The $3B Biotech With Two Shots On Goal

Edgewise Therapeutics, a $3.1B biotech company, has two major drug candidates with significant market potential. EDG-7500 for hypertrophic cardiomyopathy uses a novel mechanism (promoting heart relaxation) with superior safety profile compared to existing treatments, with efficacy data expected by June 2026. Sevasemten targets Becker Muscular Dystrophy, a disease with zero approved treatments, with pivotal trial results expected Q4 2026. The stock has tripled from its 52-week low and faces two binary catalysts this year.

03/17/2026, 7:07 AM • Benzinga

BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

BridgeBio Pharma stock surged 12.60% following William Blair's initiation of coverage with an Outperform rating and $93.03 price target. The analyst highlighted the company's accelerating Attruby launch, near-term NDA submissions for disease-modifying therapies, and a strong pipeline in rare genetic diseases including achondroplasia and autosomal dominant hypocalcemia. BridgeBio's products are positioned as next-generation alternatives to Pfizer's market-leading tafamidis.

03/10/2026, 2:49 PM • Benzinga

Tenaya Therapeutics Stock Jumps After New Alnylam Deal

Tenaya Therapeutics shares surged 31.20% following a research collaboration agreement with Alnylam Pharmaceuticals focused on discovering genetic targets for cardiovascular disease treatments. Tenaya will validate up to 15 gene targets and receive up to $10 million in upfront payments with potential milestone payments reaching $1.13 billion. Despite the positive news, the stock remains in a bearish trend trading below its 100-day and 200-day moving averages.

03/05/2026, 1:35 PM • Benzinga

Amyloidosis Therapeutic Market to Worth Over US$ 6.37 Billion by 2033 | Astute Analytica

The global amyloidosis therapeutics market is experiencing strong growth, valued at $2.95 billion in 2024 and expected to reach $6.37 billion by 2033 with a 9.20% CAGR. Growth is driven by accelerating ATTR cardiomyopathy diagnosis through imaging technologies, rapid uptake of disease-modifying therapies in North America, and expanded reimbursement in emerging markets like China and Brazil. Five core compounds dominate the market, with chemotherapy remaining the cost-effective backbone for AL amyloidosis treatment.

01/21/2026, 10:54 AM • GlobeNewswire

Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale

Alnylam Pharmaceuticals announced its 'Alnylam 2030' five-year roadmap, targeting durable global leadership in transthyretin (TTR) diseases with plans to launch nucresiran by 2028-2030. The company projects 2026 net product revenue of $4.9-5.3 billion (71% growth), significantly above Street estimates, with TTR franchise expected to reach $4.4-4.7 billion. However, shares fell 10% on Monday despite strong guidance, as 2025 revenues narrowly missed expectations.

01/12/2026, 1:33 PM • Benzinga

Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical

Scenic Biotech announced a license and research agreement with Ono Pharmaceutical to utilize its Cell-Seq platform for discovering novel therapeutic targets. This marks Scenic's fourth major pharmaceutical collaboration, joining existing partnerships with Genentech, Bristol Myers Squibb, and Alnylam.

01/07/2026, 5:00 AM • GlobeNewswire